Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-gen... CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1 | -3.125 | 3.2 | 3.23 | 2.68 | 602753 | 2.96127805 | CS |
| 4 | 0.51 | 19.6911196911 | 2.59 | 3.56 | 2.52 | 563688 | 2.98443205 | CS |
| 12 | 0.02 | 0.649350649351 | 3.08 | 3.56 | 2.37 | 507157 | 2.85930883 | CS |
| 26 | -0.28 | -8.28402366864 | 3.38 | 3.87 | 2.37 | 645727 | 3.14324053 | CS |
| 52 | -1.16 | -27.2300469484 | 4.26 | 5.28 | 2.215 | 853902 | 3.43892654 | CS |
| 156 | -37.52 | -92.368291482 | 40.62 | 41.09 | 2.215 | 722811 | 8.28098017 | CS |
| 260 | -81.89 | -96.3525120602 | 84.99 | 133 | 2.215 | 792747 | 33.12552305 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
